CK2α Inhibitor Compounds Targeting ATP and αD Binding Sites

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing CK2α inhibitors target the highly conserved ATP binding site, leading to poor selectivity over other kinases, necessitating the development of potent and more selective inhibitors that interact with the αD site to effectively inhibit CK2α activity in diseases such as cancer and other conditions.

Innovation Solution

Development of novel therapeutic compounds that inhibit CK2α by binding to the catalytic ATP site and interacting with the αD site, providing enhanced selectivity over other kinases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing CK2α inhibitors target the highly conserved ATP binding site, then CK2α activity is inhibited, but selectivity over other kinases deteriorates

Engineering Contradiction:

ImproveCK2α inhibition efficacyVSAvoidselectivity over other kinases

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The inhibitor molecule is divided into two distinct functional segments: one segment binds to the catalytic ATP site to provide CK2α inhibition, while another segment binds to the αD site to provide selectivity. This segmentation allows each part to perform its specific function independently, resolving the contradiction between efficacy and selectivity.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

Different parts of the inhibitor molecule have different binding characteristics tailored to specific sites on CK2α. The first binding region has properties optimized for the catalytic ATP site interaction, while the second binding region has properties optimized for the αD site interaction. This local differentiation enables simultaneous achievement of inhibition and selectivity.

Inventive Principle:

Principle #3Local quality

2Power

If inhibitors bind to the catalytic ATP site to drive potent enzyme inhibition, then CK2α activity is effectively inhibited, but selectivity over other kinases deteriorates

Engineering Contradiction:

Improveenzyme inhibition potencyVSAvoidselectivity over other kinases

Core Design Contradiction:

PowerVSAdaptability or versatility

Solution Approach 1:

The inhibitor combines two binding interactions in a single molecule: binding to the catalytic ATP site for potent inhibition and binding to the αD site for selectivity. This merging of two previously separate binding events into one compound allows both potency and selectivity to be achieved simultaneously.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The αD site acts as an intermediary binding region that mediates the selectivity aspect of the interaction. While the catalytic site provides the primary inhibition mechanism, the αD site serves as an additional interaction point that distinguishes CK2α inhibition from off-target kinase inhibition.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20260070901A1Novel compounds as CK2 inhibitors

Publication Date: 2026.03.12 CAMBRIDGE ENTERPRISE LTD

AI summary

Provided are compounds of the Formula I, and salts, hydrates and solvates thereof:wherein RL, L and RR are each as defined in the specification. The compounds are inhibitors of Casein Kinase 2 alpha (CK2α) and are useful for the treatment and/or prevention of diseases and conditions in which CK2α activity is implicated, such as, for example, but not limited to, the treatment and/or prevention of proliferative disorders (e.g. cancer), viral infections, inflammation, diabetes, vascular and ischemic disorders, neurodegeneration and the regulation of circadian rhythm. The present invention also relates to pharmaceutical compositions comprising the compounds defined herein, to processes for synthesizing these compounds and to their use for the treatment of diseases and/or conditions in which CK2α activity is implicated.